Celcuity Inc. CELC 深 滬
等待開盤 04-02 09:30:00 美东时间
112.93
-1.210
-1.06%
華盛通- 最 高117.91
- 今 開115.60
- 成交量 73.66万股
- 最 低 112.39
- 昨 收 114.14
- 總市值 54.59亿
- 52周最高 120.315
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 9.02
- 委 比 19.76%
- 總股本 4833.67万
- 歷史最高 120.315
- 量 比 0.84
- 振 幅 4.84%
- 歷史最低 4.03
- 每 手 1
- 風險率 39.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Needham Reiterates Buy on Celcuity, Maintains $122 Price Target
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $122 price target.
03-26 20:19
财报速睇 | Celcuity Inc. 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损1.77亿美元，同比亏损扩大58.4%
华盛资讯3月26日讯，Celcuity Inc.公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损1.77亿美元，同比亏损扩大58.4%。
03-26 19:46
财报速睇 | Celcuity Inc. 2025财年Q4营收0.00亿美元，同比增长0.0%；归母净利润亏损0.51亿美元，同比亏损扩大39.1%
华盛资讯3月26日讯，Celcuity Inc.公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比增长0.0%，归母净利润亏损0.51亿美元，同比亏损扩大39.1%。
03-26 04:32
Celcuity Q4 Adj. EPS $(0.73) Beats $(1.04) Estimate
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.04) by 29.94 percent. This is a 2.67 percent increase over losses of $(0.75) per share from the same
03-26 04:01
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
< Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company, announced it will release its 2025 fourth-quarter and full-year financial results on March 25, 2026, after market close. Management will host a conference call and webcast at 4:30 p.m. ET the same day to discuss the results and provide a corporate update. Celcuity is focused on developing targeted therapies for oncology, with its lead candidate being gedatolisib, a pan-PI3K a...
03-18 12:00
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Needham Maintains Buy on Celcuity, Raises Price Target to $122
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $95 to $122.
03-10 18:21
Celcuity Reveals Publication Of Efficacy And Safety Results From The PIK3CA Wild-Type Cohort Of The Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, An Investigational Pan-PI3K/mTORC1/2 Inhibitor, In The Journal Of Clinical Oncology
elcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type ("WT")
03-10 05:46
